Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SRPT Stock Summary
Top 10 Correlated ETFs
SRPT
In the News
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Regenxbio reported some favorable data from a phase 1 clinical trial. Sarepta Therapeutics has a medicine on the market for the same target.
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.
Biopharma company Sarepta Therapeutics is on the verge of reaching sustained profits. Last year was miserable for Enphase Energy, and this year isn't likely to be much better thanks to the tepid demand for residential solar solutions.
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
Sarepta Therapeutics is trying to widen its market for Elevidys. Regulators should deliver a verdict in early March.
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y
Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Is It Too Late to Buy Sarepta Therapeutics Stock?
Sarepta Therapeutics faced some issues last year, but it earned approval for an important medicine. The biotech is on the verge of another key regulatory nod that should help improve its financial results.
Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT)
Sarepta Therapeutics (SRPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2023 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 28, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2023 financial results and to provide a corporate update. The event will be webcast live under the investor relati.
SRPT Financial details
SRPT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 5.17 | 6.93 | 8.64 | 11.48 | 13.46 | |
Net income per share | -9.71 | -7.11 | -5.15 | -8.66 | -5.8 | |
Operating cash flow per share | -6.2 | 1.38 | -5.45 | -4 | -5.42 | |
Free cash flow per share | -7.05 | 0.32 | -5.93 | -4.38 | -6.37 | |
Cash per share | 15.28 | 24.87 | 26.04 | 24.48 | 18.14 | |
Book value per share | 11.11 | 9.77 | 11.42 | 4.74 | 9.3 | |
Tangible book value per share | 10.94 | 9.6 | 11.24 | 4.64 | 8.98 | |
Share holders equity per share | 11.11 | 9.77 | 11.42 | 4.74 | 9.3 | |
Interest debt per share | 10.43 | 17.02 | 18.13 | 20.56 | 13.83 | |
Market cap | 9.5B | 13.29B | 7.32B | 10.53B | 8.91B | |
Enterprise value | 9.39B | 12.86B | 6.34B | 11.18B | 9.88B | |
P/E ratio | -13.28 | -23.98 | -17.47 | -14.97 | -16.62 | |
Price to sales ratio | 24.94 | 24.6 | 10.43 | 11.29 | 7.17 | |
POCF ratio | -20.81 | 123.64 | -16.51 | -32.37 | -17.78 | |
PFCF ratio | -18.3 | 525.94 | -15.19 | -29.56 | -15.14 | |
P/B Ratio | 11.61 | 17.44 | 7.89 | 27.35 | 10.37 | |
PTB ratio | 11.61 | 17.44 | 7.89 | 27.35 | 10.37 | |
EV to sales | 24.67 | 23.81 | 9.03 | 11.98 | 7.95 | |
Enterprise value over EBITDA | -20.01 | -24.29 | -15.38 | -23.61 | -36.88 | |
EV to operating cash flow | -20.58 | 119.64 | -14.31 | -34.36 | -19.72 | |
EV to free cash flow | -18.09 | 508.93 | -13.16 | -31.39 | -16.79 | |
Earnings yield | -0.08 | -0.04 | -0.06 | -0.07 | -0.06 | |
Free cash flow yield | -0.05 | 0 | -0.07 | -0.03 | -0.07 | |
Debt to equity | 0.9 | 1.66 | 1.52 | 4.2 | 1.46 | |
Debt to assets | 0.4 | 0.42 | 0.45 | 0.52 | 0.38 | |
Net debt to EBITDA | 0.22 | 0.81 | 2.37 | -1.37 | -3.62 | |
Current ratio | 5.55 | 5.97 | 5.75 | 4.13 | 3.95 | |
Interest coverage | -17.03 | -9.41 | -7.08 | -10.07 | -12.17 | |
Income quality | 0.64 | -0.19 | 1.06 | 0.46 | 0.93 | |
Dividend Yield | 0.03 | 0.02 | 0 | 0 | 0 | |
Payout ratio | -0.34 | -0.52 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.75 | 0.59 | 0.4 | 0.48 | 0.39 | |
Research and developement to revenue | 1.47 | 1.34 | 1.1 | 0.94 | 0.71 | |
Intangibles to total assets | 0.01 | 0 | 0 | 0 | 0.01 | |
Capex to operating cash flow | 0.14 | -0.76 | 0.09 | 0.09 | 0.17 | |
Capex to revenue | -0.16 | -0.15 | -0.05 | -0.03 | -0.07 | |
Capex to depreciation | -2.05 | -3.05 | -1.01 | -0.74 | -1.48 | |
Stock based compensation to revenue | 0.21 | 0.2 | 0.16 | 0.25 | 0.15 | |
Graham number | 49.29 | 39.54 | 36.39 | 30.38 | 34.84 | |
ROIC | -0.33 | -0.27 | -0.19 | -0.26 | -0.12 | |
Return on tangible assets | -0.39 | -0.19 | -0.13 | -0.23 | -0.17 | |
Graham Net | 3.75 | -0.83 | 1.45 | -5.63 | -2.57 | |
Working capital | 1.2B | 2.07B | 2.15B | 1.94B | 1.93B | |
Tangible asset value | 805.69M | 748.13M | 913.77M | 377.37M | 829.72M | |
Net current asset value | 464.28M | 262.24M | 384.13M | -185.56M | 174.09M | |
Invested capital | 0.9 | 1.66 | 1.52 | 4.2 | 1.46 | |
Average receivables | 71.49M | 116.26M | 155.11M | 215.67M | 349.7M | |
Average payables | 50.96M | 89.59M | 93.92M | 86.31M | 130.4M | |
Average inventory | 148.41M | 201.67M | 209.09M | 195.09M | 263.41M | |
Days sales outstanding | 90.03 | 93.65 | 89.26 | 101.59 | 129.08 | |
Days payables outstanding | 439.23 | 639.74 | 288.62 | 249.98 | 400.38 | |
Days of inventory on hand | 1.11K | 1.34K | 700.34 | 531.82 | 783.83 | |
Receivables turnover | 4.05 | 3.9 | 4.09 | 3.59 | 2.83 | |
Payables turnover | 0.83 | 0.57 | 1.26 | 1.46 | 0.91 | |
Inventory turnover | 0.33 | 0.27 | 0.52 | 0.69 | 0.47 | |
ROE | -0.87 | -0.73 | -0.45 | -1.83 | -0.62 | |
Capex per share | -0.85 | -1.05 | -0.47 | -0.38 | -0.95 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.18 | 2.87 | 2.95 | 3.73 | 3.76 | |
Net income per share | -1.34 | -5.86 | -0.27 | -0.46 | 0.43 | |
Operating cash flow per share | -1.14 | -2.37 | -1.38 | -1.29 | -0.52 | |
Free cash flow per share | -1.23 | -2.48 | -1.58 | -1.75 | -0.7 | |
Cash per share | 24.48 | 21.34 | 20.99 | 19.5 | 15.87 | |
Book value per share | 4.74 | 8.08 | 8.36 | 8.6 | 8.14 | |
Tangible book value per share | 4.64 | 8 | 8.16 | 8.38 | 7.86 | |
Share holders equity per share | 4.74 | 8.08 | 8.36 | 8.6 | 8.14 | |
Interest debt per share | 19.99 | 14.68 | 19.14 | 19.11 | 11.73 | |
Market cap | 10.53B | 12.15B | 10.15B | 10.78B | 10.18B | |
Enterprise value | 11.18B | 12.57B | 10.67B | 11.6B | 11.15B | |
P/E ratio | -24.1 | -5.88 | -106.04 | -65.8 | 55.76 | |
Price to sales ratio | 40.75 | 47.95 | 38.87 | 32.47 | 25.66 | |
POCF ratio | -113.97 | -58.04 | -83.07 | -93.94 | -186.3 | |
PFCF ratio | -104.93 | -55.53 | -72.46 | -69.24 | -138.17 | |
P/B Ratio | 27.35 | 17.05 | 13.7 | 14.1 | 11.85 | |
PTB ratio | 27.35 | 17.05 | 13.7 | 14.1 | 11.85 | |
EV to sales | 43.26 | 49.59 | 40.83 | 34.97 | 28.1 | |
Enterprise value over EBITDA | -137.2 | -116.66 | -105.23 | 929.64 | -391.81 | |
EV to operating cash flow | -121.01 | -60.03 | -87.27 | -101.17 | -204.01 | |
EV to free cash flow | -111.41 | -57.43 | -76.11 | -74.57 | -151.31 | |
Earnings yield | -0.01 | -0.04 | 0 | 0 | 0 | |
Free cash flow yield | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | |
Debt to equity | 4.2 | 1.81 | 2.28 | 2.22 | 1.46 | |
Debt to assets | 0.52 | 0.42 | 0.54 | 0.54 | 0.38 | |
Net debt to EBITDA | -7.98 | -3.87 | -5.06 | 66.46 | -34.03 | |
Current ratio | 4.13 | 4.63 | 4.96 | 5.44 | 3.95 | |
Interest coverage | -15.97 | -21.84 | -25.56 | -3.99 | -1.47 | |
Income quality | 0.85 | 0.41 | 5.11 | 2.8 | -1.2 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.47 | 0.44 | 0.45 | 0.36 | 0.88 | |
Research and developement to revenue | 0.83 | 0.97 | 0.93 | 0.59 | 0.49 | |
Intangibles to total assets | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Capex to operating cash flow | 0.09 | 0.05 | 0.15 | 0.36 | 0.35 | |
Capex to revenue | -0.03 | -0.04 | -0.07 | -0.12 | -0.05 | |
Capex to depreciation | -0.75 | -0.84 | -1.66 | -3.74 | -1.25 | |
Stock based compensation to revenue | 0.2 | 0.16 | 0.18 | 0.14 | 0.12 | |
Graham number | 11.97 | 32.64 | 7.13 | 9.44 | 8.9 | |
ROIC | -0.06 | -0.07 | -0.09 | -0.01 | 0.01 | |
Return on tangible assets | -0.04 | -0.17 | -0.01 | -0.01 | 0.01 | |
Graham Net | -5.63 | -1.67 | -2.37 | -2.52 | -2.25 | |
Working capital | 1.94B | 1.95B | 1.97B | 2B | 1.93B | |
Tangible asset value | 377.37M | 705.55M | 723.39M | 744.86M | 829.72M | |
Net current asset value | -185.56M | 141.34M | 88.14M | 105.5M | 174.09M | |
Invested capital | 4.2 | 1.81 | 2.28 | 2.22 | 1.46 | |
Average receivables | 241.57M | 273.89M | 277.62M | 310.71M | 396.98M | |
Average payables | 107.17M | 101.29M | 108.25M | 98.87M | 126.43M | |
Average inventory | 212.58M | 203.32M | 214.78M | 235.44M | 283.44M | |
Days sales outstanding | 90.44 | 102.28 | 92.04 | 96.09 | 99.74 | |
Days payables outstanding | 280.16 | 274.26 | 289.58 | 213.78 | 335.99 | |
Days of inventory on hand | 596.03 | 520.91 | 598.37 | 593.12 | 657.76 | |
Receivables turnover | 1 | 0.88 | 0.98 | 0.94 | 0.9 | |
Payables turnover | 0.32 | 0.33 | 0.31 | 0.42 | 0.27 | |
Inventory turnover | 0.15 | 0.17 | 0.15 | 0.15 | 0.14 | |
ROE | -0.28 | -0.73 | -0.03 | -0.05 | 0.05 | |
Capex per share | -0.1 | -0.11 | -0.2 | -0.46 | -0.18 |
SRPT Frequently Asked Questions
What is Sarepta Therapeutics, Inc. stock symbol ?
Sarepta Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol SRPT
Is Sarepta Therapeutics, Inc. buy or a sell ?
18 stock analysts have 18 predictions with a medium analyst target price of $137.11. The lowest prediction is $80 and the highest is $187
What is SRPT stock prediction ?
What is Sarepta Therapeutics, Inc. stock quote today ?
Sarepta Therapeutics, Inc. stock price is $128.805 today.
Is Sarepta Therapeutics, Inc. stock public?
Yes, Sarepta Therapeutics, Inc. is a publicly traded company.